Showing results (281-290 of 312) with videos related to
Sort By:
Pageof 32
Cancer|August 30, 2008
Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02Jarrod P Holmes, Jeremy D Gates, Linda C Benavides, et al.Expert Review of Vaccines|February 22, 2011
Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccinesLinda C Benavides, Alan K Sears, Jeremy D Gates, et al.Journal of Vascular Surgery|September 14, 2019
Emergency intraoperative vascular surgery consultations at a tertiary academic centerStuart L Blackwood, James J O'Leary, Rebecca E Scully, et al.Cancer|October 13, 2011
Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02Elizabeth A Mittendorf, Guy T Clifton, Jarrod P Holmes, et al.Human Vaccines|April 26, 2008
Monitoring circulating tumor cells in cancer vaccine trialsJ D Gates, L C Benavides, A Stojadinovic, et al.Nature|October 10, 1996
A massive phytoplankton bloom induced by an ecosystem-scale iron fertilization experiment in the equatorial Pacific OceanK H Coale, K S Johnson, S E Fitzwater, et al.Nanoscale|August 2, 2018
Nanoparticle localization in blood vessels: dependence on fluid shear stress, flow disturbances, and flow-induced changes in endothelial physiologyM Juliana Gomez-Garcia, Amber L Doiron, Robyn R M Steele, et al.Shock (Augusta, Ga.)|February 10, 2015
Automated analysis of vital signs to identify patients with substantial bleeding before hospital arrival: a feasibility studyJianbo Liu, Maxim Y Khitrov, Jonathan D Gates, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2009
The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02Linda C Benavides, Jeremy D Gates, Mark G Carmichael, et al.Journal of the American College of Surgeons|February 21, 2009
Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patientsJeremy D Gates, Mark G Carmichael, Linda C Benavides, et al.Pageof 32